Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Br Med J (Clin Res Ed) ; 290(6465): 341-4, 1985 Feb 02.
Artigo em Inglês | MEDLINE | ID: mdl-3917812

RESUMO

Six patients with venous thromboembolism were treated with heparin, administered intravenously by a constant infusion pump. The initial daily dose of heparin was adjusted to keep the activated partial thromboplastin time, sampled at 0800, between 1.5 and 2.5 times the control level. Once that level was obtained, this dose was kept constant. Anticoagulation was thereafter measured, every four hours for 48 hours, by activated partial thromboplastin time, thrombin time, and coagulation factor Xa inhibition assay. The results of all three coagulation tests showed a circadian variation in the six patients. Maximum values were achieved at night and minimum values in the morning. These circadian variations were reproduced for two consecutive days. Differences between night and morning values reached almost 50% for activated partial thromboplastin time, 60% for thrombin time, and 40% for factor Xa inhibition assay. This circadian variation resulted from two rhythms, a circadian rhythm lasting 24 hours and an ultradian rhythm lasting 12 hours, which were detected by cosinor analysis for each coagulation test (p less than 0.01). A circadian rhythm was detected individually in most of the patients for each coagulation test (p less than 0.05). All patients had a nocturnal peak in activated partial thromboplastin time on both days. In four patients this peak exceeded the upper desired limit of activated partial thromboplastin time. These rhythms should be taken into account when evaluating the dosage of heparin to be administered.


Assuntos
Anticoagulantes , Ritmo Circadiano , Heparina/administração & dosagem , Embolia Pulmonar/tratamento farmacológico , Tromboflebite/tratamento farmacológico , Idoso , Testes de Coagulação Sanguínea , Feminino , Heparina/uso terapêutico , Humanos , Infusões Parenterais , Masculino , Pessoa de Meia-Idade , Tempo de Tromboplastina Parcial
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA